Indefinite Delivery Contract SPE2DR25D9101

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain has awarded a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, under the SPE2DB program, covers a wide range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

The IDC enables the DLA to issue firm fixed-price delivery orders for various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This contract positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites. The original solicitation, expected to be issued in March 2024, is for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts, which will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. The procurement is fully competitive, with the intent to make multiple regional awards to ensure the resiliency and access to vital pharmaceuticals for the Department of Defense.